van der Poel H - Search Results

1

The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.

van der Poel H, Grivas N, van Leeuwen P, Heijmink S, Schoots I. van der Poel H, et al. Among authors: van leeuwen p. World J Urol. 2019 Aug;37(8):1485-1490. doi: 10.1007/s00345-019-02677-y. Epub 2019 Feb 20. World J Urol. 2019. PMID: 30788590 Review.

2

Quantitative light microscopy in urological oncology.

van der Poel HG, Schaafsma HE, Vooijs GP, Debruyne FM, Schalken JA. van der Poel HG, et al. J Urol. 1992 Jul;148(1):1-13. doi: 10.1016/s0022-5347(17)36494-7. J Urol. 1992. PMID: 1613843 Review. No abstract available.

3

Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer.

van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA. van der Poel HG, et al. Among authors: van stratum p. Urology. 1996 Sep;48(3):357-64. doi: 10.1016/S0090-4295(96)00210-5. Urology. 1996. PMID: 8804485 Free article. Clinical Trial.

4

Intratumoral nuclear morphologic heterogeneity in prostate cancer.

van der Poel HG, Oosterhof GO, Schaafsma HE, Debruyne FM, Schalken JA. van der Poel HG, et al. Urology. 1997 Apr;49(4):652-7. doi: 10.1016/s0090-4295(96)00557-2. Urology. 1997. PMID: 9111646 Free article.

5

Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer.

Van der Poel HG, Van Balken MR, Schamhart DH, Peelen P, de Reijke T, Debruyne FM, Schalken JA, Witjes JA. Van der Poel HG, et al. Among authors: van balken mr. Urology. 1998 Jan;51(1):44-50. doi: 10.1016/s0090-4295(97)00496-2. Urology. 1998. PMID: 9457287

6

Consecutive quantitative cytology in bladder cancer.

van der Poel HG, van Rhijn BW, Peelen P, Debruyne FM, Boon ME, Schalken JA. van der Poel HG, et al. Among authors: van rhijn bw. Urology. 2000 Oct 1;56(4):584-8. doi: 10.1016/s0090-4295(00)00726-3. Urology. 2000. PMID: 11018610

7

Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer.

Sedelaar JP, van Leenders GJ, Hulsbergen-van de Kaa CA, van der Poel HG, van der Laak JA, Debruyne FM, Wijkstra H, de la Rosette JJ. Sedelaar JP, et al. Among authors: van leenders gj, van der laak ja, van der poel hg. Eur Urol. 2001 Sep;40(3):285-93. doi: 10.1159/000049788. Eur Urol. 2001. PMID: 11684844

8

Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.

Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, Ten Bokkel Huinink WW, van de Vijver M, Witjes JA, Horenblas S. Spermon JR, et al. Among authors: van der poel hg, van de vijver m. Urology. 2002 Jun;59(6):923-9. doi: 10.1016/s0090-4295(02)01528-5. Urology. 2002. PMID: 12031382

9

Smart drugs in prostate cancer.

van der Poel HG. van der Poel HG. Eur Urol. 2004 Jan;45(1):1-17. doi: 10.1016/j.eururo.2003.08.011. Eur Urol. 2004. PMID: 14667509 Review.

10

Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.

van der Poel HG. van der Poel HG. J Urol. 2004 Oct;172(4 Pt 1):1333-7. doi: 10.1097/01.ju.0000138829.97838.19. J Urol. 2004. PMID: 15371835

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

512 results

Search Page